Characterization of genotype IV hepatitis E virus-like particles expressed in E.coli

Rushi Liu; Chufan Tan; Junwen Wu; Ye Xu; Xiaofeng Li; Zhihong Zhong; Sang Li; Yilan Qiu; Bo Feng

Heliyon (Apr 2023)

Characterization of genotype IV hepatitis E virus-like particles expressed in E.coli

Rushi Liu,
Chufan Tan,
Junwen Wu,
Ye Xu,
Xiaofeng Li,
Zhihong Zhong,
Sang Li,
Yilan Qiu,
Bo Feng

Affiliations

Rushi Liu: Laboratory of Medical Molecular and Immunological Diagnostics, School of Medicine, Hunan Normal University, Changsha, 410013, China
Chufan Tan: Laboratory of Medical Molecular and Immunological Diagnostics, School of Medicine, Hunan Normal University, Changsha, 410013, China
Junwen Wu: Nanya Middle School of Changsha, Changsha, 410129, China
Ye Xu: Laboratory of Medical Molecular and Immunological Diagnostics, School of Medicine, Hunan Normal University, Changsha, 410013, China
Xiaofeng Li: Laboratory of Medical Molecular and Immunological Diagnostics, School of Medicine, Hunan Normal University, Changsha, 410013, China
Zhihong Zhong: Laboratory of Medical Molecular and Immunological Diagnostics, School of Medicine, Hunan Normal University, Changsha, 410013, China
Sang Li: Laboratory of Medical Molecular and Immunological Diagnostics, School of Medicine, Hunan Normal University, Changsha, 410013, China
Yilan Qiu: School of Life Science, Hunan Normal University, Changsha, 410081, China; Corresponding author.
Bo Feng: The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, 410008, China; Corresponding author.

Journal volume & issue: Vol. 9, no. 4
p. e15284

Abstract

Read online

HEV (Hepatitis E virus) is an infectious disease transmitted between humans and animals, which poses a severe threat to the biological safety and property throughout the world. The disease is especially severe in patients with potential liver cirrhosis and women during pregnancy. There is no specific and thorough HEV treatment at present. The development of hepatitis E virus vaccine is vital to the prevention of viral hepatitis worldwide. Since HEV cannot grow adequately in vitro, vaccine developed by devitalized virus particles does not work. Exploration of HEV-like structures is essential for the development of functional vaccines against HEV infection. ORF2 encodes the structural proteins of HEV, some of which can automatically assemble into virus-like particles (VLP) in this experiment, the recombinant capsid protein p27 was expressed in E. coli and the VLP formed by p27 was used to immunize mice. The results showed that the VLP formed by recombinant P27 had similar particle size to that of HEV; the immune dose produced by p27 was positively correlated with the immune effect. Compared with other genetic engineering subunit vaccines, P27 protein has a better application prospect.

Published in Heliyon

ISSN: 2405-8440 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Science: Science (General); Social Sciences: Social sciences (General)
Website: https://www.cell.com/heliyon/home

About the journal

Abstract

Keywords